Compare Stocks: TROV, XBIT, PMVP, and ELTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELTX Elicio Therapeutics	$2.35 -2.5%	$3.05	$2.34 ▼ $16.00	$63.34M	1.29	270,074 shs	324,603 shs
PMVP PMV Pharmaceuticals	$1.34 +3.9%	$1.25	$1.02 ▼ $1.88	$68.96M	1.37	621,334 shs	1.16 million shs
TROV Cardiff Oncology	$1.56	$16.75	$0.70 ▼ $3.46	$17.18M	1.04	648,892 shs	885,068 shs
XBIT XBiotech	$2.18 -0.9%	$2.28	$2.09 ▼ $3.44	$67.07M	0.85	52,126 shs	45,361 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELTX Elicio Therapeutics	0.00%	-10.74%	-24.45%	-83.03%	-79.01%
PMVP PMV Pharmaceuticals	0.00%	+6.61%	+8.40%	+22.86%	-11.64%
TROV Cardiff Oncology	0.00%	0.00%	0.00%	0.00%	-28.11%
XBIT XBiotech	0.00%	-4.35%	-3.08%	-7.17%	-24.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELTX Elicio Therapeutics	$2.35 -2.5%	$3.05	$2.34 ▼ $16.00	$63.34M	1.29	270,074 shs	324,603 shs
PMVP PMV Pharmaceuticals	$1.34 +3.9%	$1.25	$1.02 ▼ $1.88	$68.96M	1.37	621,334 shs	1.16 million shs
TROV Cardiff Oncology	$1.56	$16.75	$0.70 ▼ $3.46	$17.18M	1.04	648,892 shs	885,068 shs
XBIT XBiotech	$2.18 -0.9%	$2.28	$2.09 ▼ $3.44	$67.07M	0.85	52,126 shs	45,361 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELTX Elicio Therapeutics	0.00%	-10.74%	-24.45%	-83.03%	-79.01%
PMVP PMV Pharmaceuticals	0.00%	+6.61%	+8.40%	+22.86%	-11.64%
TROV Cardiff Oncology	0.00%	0.00%	0.00%	0.00%	-28.11%
XBIT XBiotech	0.00%	-4.35%	-3.08%	-7.17%	-24.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELTX Elicio Therapeutics	2.50	Moderate Buy	$19.75	740.43% Upside
PMVP PMV Pharmaceuticals	2.80	Moderate Buy	$4.33	223.38% Upside
TROV Cardiff Oncology	0.00	N/A	N/A	N/A
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TROV, XBIT, PMVP, and ELTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
9/1/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ELTX Elicio Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	PMVP PMV Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.00
6/30/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	$0.09 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.97 per share	N/A
TROV Cardiff Oncology	$250K	68.71	N/A	N/A	$0.94 per share	1.66
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELTX Elicio Therapeutics	-$39.57M	-$2.17	N/A	N/A	N/A	N/A	-1,266.43%	-139.94%	11/12/2026 (Estimated)
PMVP PMV Pharmaceuticals	-$77.74M	-$1.42	N/A	N/A	N/A	N/A	-78.11%	-70.13%	11/11/2026 (Estimated)
TROV Cardiff Oncology	-$16.41M	-$2.80	N/A	N/A	N/A	-3,688.31%	-202.00%	-122.92%	N/A
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A

Latest TROV, XBIT, PMVP, and ELTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/13/2026	Q2 2026	ELTX Elicio Therapeutics	-$0.5375	-$0.43	+$0.1075	-$0.43	N/A	N/A
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TROV Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELTX Elicio Therapeutics	1.20	2.77	2.77
PMVP PMV Pharmaceuticals	N/A	7.70	7.70
TROV Cardiff Oncology	0.12	2.37	2.37
XBIT XBiotech	N/A	33.15	33.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELTX Elicio Therapeutics	35.03%
PMVP PMV Pharmaceuticals	90.20%
TROV Cardiff Oncology	9.99%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ELTX Elicio Therapeutics	28.65%
PMVP PMV Pharmaceuticals	10.15%
TROV Cardiff Oncology	0.60%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELTX Elicio Therapeutics	N/A	26.28 million	18.75 million	Not Optionable
PMVP PMV Pharmaceuticals	50	53.46 million	48.03 million	Optionable
TROV Cardiff Oncology	N/A	11.01 million	N/A	Not Optionable
XBIT XBiotech	100	30.49 million	21.10 million	Optionable

TROV, XBIT, PMVP, and ELTX Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Stock Passes Below 200 Day Moving Average - Here's Why

September 3, 2026 | americanbankingnews.com

XBiotech (NASDAQ:XBIT) Shares Cross Below 200-Day Moving Average - Time to Sell?

September 3, 2026 | marketbeat.com

XBiotech (NASDAQ:XBIT) Share Price Passes Above 50 Day Moving Average - Here's What Happened

August 26, 2026 | marketbeat.com

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS

August 13, 2026 | marketbeat.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

TROV, XBIT, PMVP, and ELTX Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

$2.35 -0.06 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.41 +0.06 (+2.55%)

As of 07:30 PM Eastern

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

PMV Pharmaceuticals NASDAQ:PMVP

$1.34 +0.05 (+3.88%)

Closing price 04:00 PM Eastern

Extended Trading

$1.35 +0.01 (+0.75%)

As of 07:30 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Cardiff Oncology NASDAQ:TROV

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

XBiotech NASDAQ:XBIT

$2.18 -0.02 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 0.00 (0.00%)

As of 07:30 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TROV, XBIT, PMVP, and ELTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TROV, XBIT, PMVP, and ELTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TROV, XBIT, PMVP, and ELTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TROV, XBIT, PMVP, and ELTX Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

PMV Pharmaceuticals NASDAQ:PMVP

Cardiff Oncology NASDAQ:TROV

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TROV, XBIT, PMVP, and ELTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TROV, XBIT, PMVP, and ELTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TROV, XBIT, PMVP, and ELTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TROV, XBIT, PMVP, and ELTX Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

PMV Pharmaceuticals NASDAQ:PMVP

Cardiff Oncology NASDAQ:TROV

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools